Illumina has announced an 18-month roadmap for NovaSeq X, featuring a 40% output increase to 35 billion reads, faster turnaround times, new flow cell options, and the introduction of Q70 quality scores.
BillionToOne has launched Northstar PGx and Northstar Select CH, two liquid biopsy add-on tests for advanced solid tumor therapy selection, enabling pharmacogenomic insights and clonal hematopoiesis detection from a single blood draw.
New kit cuts sample-to-result time to 75 minutes while maintaining sensitivity for drug metabolism studies.
Hospital teams can trial the company’s BSI/AMR test and preview the LiDia-SEQ system ahead of commercial launch.
Read More
The precision medicine company now has 57 approvals in the US and 43 in Japan for its FoundationOne CDx and FoundationOne Liquid CDx tests.
Read More
The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
Read More
The platform features enhanced speed and digital connectivity for liquid biopsy applications, with commercial release planned for mid-2026.
Read More
UMBS-seq preserves DNA integrity while maintaining accuracy for cancer biomarker detection in liquid biopsies and tissue samples.
Read More
The proposed order would shift these test systems to Class II with special controls, replacing the current PMA requirement for companion diagnostics and related oncology assays.
Read More
Two studies show the advanced technique can identify chromosomal abnormalities missed by traditional genetic testing methods.
Read MoreStudies demonstrate artificial intelligence achieving 93% cancer diagnostic accuracy and enabling noninvasive tumor analysis through spinal fluid testing.
Read More
The collaboration combines SOPHiA’s DDM platform with Element’s AVITI sequencing systems to streamline genomic workflows for precision medicine research.
Read More
Researchers identify critical flaws in Oxford Nanopore devices that could expose or alter genetic data without detection.
Read More
The new module enables one-step reverse transcription and amplification, removing cDNA prep and supporting applications in translational research, cell and gene therapy manufacturing, and diagnostic development.
Read More
The GeneSight test results led to faster initial remission and response in patients with major depressive disorder, with benefits persisting over six months.
Read More
The collaboration will focus on creating a cortisol biosensor for stress and metabolic health testing using luminescent biosensors and AI-guided interpretation.
Read More
The designation accelerates regulatory review for GeneDx’s ExomeDx and GenomeDx testing platforms designed to diagnose rare diseases.
Read More
The upgrade leverages technology by Ultima Genomics and processing at the Gene by Gene lab.
Read More